Our Focus
Current treatment options for patients experiencing a stroke or heart attack are limited and delay the re-establishment of blood flow.
TSci is dedicated to transforming standards of care, by bringing a simple intravenous biotherapy to the patient, closer to the time of onset.
TSci's bio-inspired solution is
-
A low dose, efficacious, safer dual thrombolytic Rx
-
Based on a clinically validated mechanism
-
To be given on suspicion of a stroke or heart attack
Clinical Trials
TSci’s novel mproUK-based, low-dose dual thrombolytic therapy has completed a Phase 1 clinical study and has been evaluated in a Phase 2 clinical trial in ischemic stroke patients, with both studies supporting its safety and tolerability, see 2023 JAMA Neurology publication below.
Science
TSci’s thrombolytic approach is centered on mproUK, its proprietary mutant pro-urokinase compound, which is designed to selectively dissolve pathologic, occlusive clots while preserving intact fibrin, including protective hemostatic plugs.
In TSci’s low-dose dual therapy, a small amount of tPA is used only to prime the clot surface. Once the clot surface has been degraded, tPA is rapidly cleared from the bloodstream, allowing mproUK to selectively target and dissolve the degraded clot.
Because mproUK remains in its inactive pro-enzymatic form unless it encounters a degraded clot, it is expected to remain inactive in cases such as stroke mimics or hemorrhagic stroke before being cleared from the bloodstream. This mechanism supports the potential for earlier administration of TSci’s thrombolytic regimen on suspicion of ischemic stroke or heart attack, when rapid treatment is most critical.
Team
Management & Directors
Executive Chair of the Board
Advisory Board
Chairman of the Court,
London School of Hygiene
& Tropical Medicine
Non-Executive Chairman,
Cocoon Biotech
Professor of Medicine, Hematology
Adjunct Professor, Neurology,
Washington University
Senior Lecturer,
Harvard Medical School, Former Chief Medical Officer, Chairman & Founder, InfraReDx
1985 Nobel Peace Prize
President & CEO,
Baim Institute
for Clinical Research
Professor of Medicine,
Harvard Medical School
Chairman & Founder, PERFUSE
News
March 31, 2026
Thrombolytic Science was issued a U.S. patent strengthening its intellectual property position around mutant proUK-based low-dose dual thrombolytic therapy for stroke and acute myocardial infarction. The patent stems from the existing patent family and broadens coverage beyond the parent case to include mutant forms of proUK with point mutations in amino acid positions 297–313 of the natural proUK sequence.
October 4, 2024
September 24, 2024
May 22, 2023
October 29, 2021
Thrombolytic Science Awarded US Patent on its Novel Low-dose Dual Thrombolytic Therapy
February 10, 2021
September 5, 2018
September 18, 2017
Publications
VIEW> Gurewich V., Segarnick D. Reperfusion of Ischemia in the Heart or Brain. JPET. 2025.
VIEW> Gurewich V., Segarnick D. Fibrinolysis was Replaced Before it was Understood. KARGER 2025.
VIEW> Van der Ende, N et al. Safety and Efficacy of Dual Thrombolytic Therapy With Mutant Prourokinase and Small Bolus Alteplase for Ischemic Stroke, A Randomized Clinical Trial. JAMA Neurol. 2023.
VIEW> Gurewich V. Therapeutic Fibrinolysis: How Efficacy and Safety Can Be Improved. JACC 2016.
VIEW> Bogarty P, Brophy J. STEMI Treatment 2016: Is Outcome Improvement Stalling and If So, Why? DOI 2016.
VIEW> Pannell R, Li S, Gurewich V. Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK. PLoS One. 2015; 10(3):e0122018.
VIEW> Tomasi S, Sarmientos P, Giorda G, Gurewich V, Vercelli A. Mutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat stroke. PLoS One. 2011; 6(7):e21999
Contact
Thrombolytic Science, LLC
One Broadway, 14 FL
Cambridge, MA 02142
TSI Biyoteknoloji ve İlaç, AŞ
Yapı Kredi Blokları Levent Mah.
Cömert Sk. C Blok Apt. 1C/40
Beşiktaş, İstanbul, Türkiye
+90 212 317 4177